Ezetimibe Improves Glucose Metabolism by Ameliorating Hepatic Function in Japanese Patients with Type 2 Diabetes

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2014 May 21

PMID 24843563

Citations 5

Authors

Shinji Ichimori

Seiya Shimoda

Rieko Goto

Yasuto Matsuo

Takako Maeda

Noboru Furukawa

Junji Kawashima

Shoko Kodama

Taiji Sekigami

Satoshi Isami

Kenro Nishida

Eiichi Araki

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Aims/Introduction: Several experimental studies have shown that ezetimibe improves steatosis and insulin resistance in the liver. This suggests that ezetimibe may improve glucose metabolism, as well as lipid metabolism, by inhibiting hepatic lipid accumulation. Therefore, we compared HbA1c levels after 3 months ezetimibe treatment with baseline levels in patients with type 2 diabetes and examined the factors associated with reductions in HbA1c following ezetimibe administration.

Materials And Methods: Lipid profiles, hepatic function, and HbA1c were assessed before and after 3 months treatment with 10 mg/day ezetimibe in 96 patients with type 2 diabetes and hypercholesterolemia. Regression analysis was used to investigate associations between metabolite levels and the percentage change in HbA1c.

Results: Low-density lipoprotein-cholesterol was significantly lower after 3 months treatment compared with baseline, and HbA1c decreased in approximately 50% of patients. Univariate linear regression analyses showed that changes in HbA1c were significantly associated with serum alanine aminotransferase (ALT), the aspartate aminotransferase (AST)/ALT ratio, and age. Two-tailed chi-square tests revealed that serum ALT ≥35 IU/L and an AST/ALT ratio <1.0 were significantly associated with decreases in HbA1c following ezetimibe administration.

Conclusions: The results of the present study indicate that ezetimibe may improve glucose metabolism. Serum ALT levels and the AST/ALT ratio were useful predictors of a glucose metabolism response to ezetimibe. This trial was registered with UMIN (no. UMIN000005307). (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00147.x, 2011).

Citing Articles

Single-Atom Ce-N-C Nanozyme Ameliorates Type 2 Diabetes Mellitus by Improving Glucose Metabolism Disorders and Reducing Oxidative Stress.

Lin Y, Wang Y, Zhang Q, Gao R, Chang F, Li B Biomolecules. 2024; 14(9).

PMID: 39334959 PMC: 11430424. DOI: 10.3390/biom14091193.

Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials.

Wu H, Shang H, Wu J Endocrine. 2018; 60(2):229-239.

PMID: 29397561 DOI: 10.1007/s12020-018-1541-4.

Increased liver markers are associated with higher risk of type 2 diabetes.

Ko S, Baeg M, Han K, Ko S, Ahn Y World J Gastroenterol. 2015; 21(24):7478-87.

PMID: 26139993 PMC: 4481442. DOI: 10.3748/wjg.v21.i24.7478.

Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome.

Ohbu-Murayama K, Adachi H, Hirai Y, Enomoto M, Fukami A, Obuchi A J Diabetes Investig. 2015; 6(3):325-33.

PMID: 25969718 PMC: 4420565. DOI: 10.1111/jdi.12298.

A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus.

Sugiyama S, Jinnouchi H, Hieshima K, Kurinami N, Suzuki T, Miyamoto F Lipids Health Dis. 2015; 14:37.

PMID: 25903215 PMC: 4417230. DOI: 10.1186/s12944-015-0028-z.

References

Santomauro A, Boden G, Silva M, Rocha D, Santos R, Ursich M . Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes. 1999; 48(9):1836-41. DOI: 10.2337/diabetes.48.9.1836. View

. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(5):1702-4. DOI: 10.1053/gast.2002.36569. View

Pinto H, Baptista A, Camilo M, Valente A, SARAGOCA A, de Moura M . Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci. 1996; 41(1):172-9. DOI: 10.1007/BF02208601. View

Inoue I, Noji S, Awata T, Takahashi K, Nakajima T, Sonoda M . Bezafibrate has an antioxidant effect: peroxisome proliferator-activated receptor alpha is associated with Cu2+, Zn2+-superoxide dismutase in the liver. Life Sci. 1998; 63(2):135-44. DOI: 10.1016/s0024-3205(98)00249-5. View

Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E . Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2014; 1(5):212-28. PMC: 4020724. DOI: 10.1111/j.2040-1124.2010.00074.x. View

Davies J, Scott C, Oishi K, Liapis A, Ioannou Y . Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem. 2005; 280(13):12710-20. DOI: 10.1074/jbc.M409110200. View

Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S . Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003; 38(10):954-61. DOI: 10.1007/s00535-003-1178-8. View

Muraoka T, Aoki K, Iwasaki T, Shinoda K, Nakamura A, Aburatani H . Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism. 2010; 60(5):617-28. DOI: 10.1016/j.metabol.2010.06.008. View

Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M . Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007; 581(29):5664-70. DOI: 10.1016/j.febslet.2007.11.023. View

10.

Neuschwander-Tetri B, Caldwell S . Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003; 37(5):1202-19. DOI: 10.1053/jhep.2003.50193. View

11.

Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo R . Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab. 2004; 89(9):4649-55. DOI: 10.1210/jc.2004-0224. View

12.

Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C . Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother. 2004; 58(10):614-8. DOI: 10.1016/j.biopha.2004.09.005. View

13.

Strandberg T, Tilvis R, Pitkala K, Miettinen T . Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. J Am Coll Cardiol. 2006; 48(4):708-14. DOI: 10.1016/j.jacc.2006.04.081. View

14.

Sorbi D, Boynton J, Lindor K . The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999; 94(4):1018-22. DOI: 10.1111/j.1572-0241.1999.01006.x. View

15.

Tenenbaum A, Fisman E, Boyko V, Benderly M, Tanne D, Haim M . Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med. 2006; 166(7):737-41. DOI: 10.1001/archinte.166.7.737. View

16.

Sone H, Iimuro S, Tanaka S, Oida K, Yamasaki Y, Oikawa S . Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia. 2010; 53(3):419-28. PMC: 2815795. DOI: 10.1007/s00125-009-1622-2. View

17.

Wallerstedt S, Olsson R, Waldenstrom J . The diagnostic significance of a high ASAT-ALAT (GOT-GPT) ratio in patients with very high serum aminotransferase levels. Acta Med Scand. 1974; 195(3):227-9. View

18.

Nozaki Y, Fujita K, Yoneda M, Wada K, Shinohara Y, Takahashi H . Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol. 2009; 51(3):548-56. DOI: 10.1016/j.jhep.2009.05.017. View

19.

Lally S, Tan C, Owens D, Tomkin G . Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia. 2006; 49(5):1008-16. DOI: 10.1007/s00125-006-0177-8. View

20.

Lonardo A, Lombardini S, Scaglioni F, Ballestri S, Verrone A, Bertolotti M . Fatty liver, carotid disease and gallstones: a study of age-related associations. World J Gastroenterol. 2006; 12(36):5826-33. PMC: 4100664. DOI: 10.3748/wjg.v12.i36.5826. View